Multiparametric flow cytometry highlights B7-H3 as a novel diagnostic/therapeutic target in GD2neg/low neuroblastoma variants.
antigens
immune evation
immunotherapy
neoplasm
neuroblastoma
tumor biomarkers
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
accepted:
04
03
2021
entrez:
2
4
2021
pubmed:
3
4
2021
medline:
18
12
2021
Statut:
ppublish
Résumé
High-risk neuroblastomas (HR-NBs) are rare, aggressive pediatric cancers characterized by resistance to therapy and relapse in more than 30% of cases, despite using an aggressive therapeutic protocol including targeting of GD2. The mechanisms responsible for therapy resistance are unclear and might include the presence of GD2neg/low NB variants and/or the expression of immune checkpoint ligands such as B7-H3. Here, we describe a multiparametric flow cytometry (MFC) combining the acquisition of 10 No false positive are detected, and MFC shows high sensitivity (0.0005%). Optimized MFC identifies CD45negCD56pos NB cells in 11 out of 12 (91.6%) of BM indicated as infiltrated by CA, 7 of which coexpress high levels of GD2 and B7-H3. MFC detects CD45negCD56posGD2neg/low NB variants expressing high surface levels of B7-H3 in two patients with HR-NB (stage M) diagnosed at 53 and 139 months of age. One of them has a non-MYCN amplified tumor with unusual THpos PHOX2Bneg phenotype, which relapsed 141 months post-diagnosis with BM infiltration and a humerus lesion. All GD2neg/low NB variants are detected in patients at relapse. Kaplan-Meier analysis highlights an interesting dichotomous prognostic value of MML5, ULBPs, PVR, B7-H6, and CD47, ligands involved in NB recognition by the immune system. Our study validates a sensitive MFC analysis providing information on GD2 and B7-H3 surface expression and allowing fast, specific and sensitive evaluation of BM tumor burden. With other routinely used diagnostic and prognostic tools, MFC can improve diagnosis, prognosis, orienting novel personalized treatments in patients with GD2low/neg NB, who might benefit from innovative therapies combining B7-H3 targeting.
Sections du résumé
BACKGROUND
High-risk neuroblastomas (HR-NBs) are rare, aggressive pediatric cancers characterized by resistance to therapy and relapse in more than 30% of cases, despite using an aggressive therapeutic protocol including targeting of GD2. The mechanisms responsible for therapy resistance are unclear and might include the presence of GD2neg/low NB variants and/or the expression of immune checkpoint ligands such as B7-H3.
METHOD
Here, we describe a multiparametric flow cytometry (MFC) combining the acquisition of 10
RESULTS
No false positive are detected, and MFC shows high sensitivity (0.0005%). Optimized MFC identifies CD45negCD56pos NB cells in 11 out of 12 (91.6%) of BM indicated as infiltrated by CA, 7 of which coexpress high levels of GD2 and B7-H3. MFC detects CD45negCD56posGD2neg/low NB variants expressing high surface levels of B7-H3 in two patients with HR-NB (stage M) diagnosed at 53 and 139 months of age. One of them has a non-MYCN amplified tumor with unusual THpos PHOX2Bneg phenotype, which relapsed 141 months post-diagnosis with BM infiltration and a humerus lesion. All GD2neg/low NB variants are detected in patients at relapse. Kaplan-Meier analysis highlights an interesting dichotomous prognostic value of MML5, ULBPs, PVR, B7-H6, and CD47, ligands involved in NB recognition by the immune system.
CONCLUSIONS
Our study validates a sensitive MFC analysis providing information on GD2 and B7-H3 surface expression and allowing fast, specific and sensitive evaluation of BM tumor burden. With other routinely used diagnostic and prognostic tools, MFC can improve diagnosis, prognosis, orienting novel personalized treatments in patients with GD2low/neg NB, who might benefit from innovative therapies combining B7-H3 targeting.
Identifiants
pubmed: 33795387
pii: jitc-2020-002293
doi: 10.1136/jitc-2020-002293
pmc: PMC8021887
pii:
doi:
Substances chimiques
B7 Antigens
0
Biomarkers, Tumor
0
CD276 protein, human
0
Gangliosides
0
ganglioside, GD2
65988-71-8
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: CB and RC are coinventors of the patent: 'Therapeutic and diagnostic methods and compositions targeting 4IgB7H3 and its counterpart NK cell receptor' (Application number 11186925.1 e 05775603.3).
Références
Cancer Cell. 2015 Apr 13;27(4):450-61
pubmed: 25858804
Front Immunol. 2019 Nov 15;10:2689
pubmed: 31803194
Pediatr Blood Cancer. 2019 Aug;66(8):e27799
pubmed: 31066205
Clin Cancer Res. 2017 Aug 1;23(15):4462-4472
pubmed: 28270499
Nat Immunol. 2001 Mar;2(3):269-74
pubmed: 11224528
Front Immunol. 2019 Aug 09;10:1876
pubmed: 31447858
Proc Natl Acad Sci U S A. 2009 Oct 20;106(42):17858-63
pubmed: 19815499
Cancer Cell. 2017 Apr 10;31(4):501-515.e8
pubmed: 28399408
Front Immunol. 2020 Jun 23;11:1295
pubmed: 32714324
J Stem Cell Res Ther. 2013 Dec 12;3(Suppl 6):004
pubmed: 24729944
Cancer Res. 2004 Dec 15;64(24):9180-4
pubmed: 15604290
Cancer. 1999 Jul 15;86(2):364-72
pubmed: 10421273
Cancer Cell. 2007 Jun;11(6):539-54
pubmed: 17560335
Blood Rev. 2018 Nov;32(6):480-489
pubmed: 29709247
Clin Cancer Res. 2019 Aug 1;25(15):4761-4774
pubmed: 31068371
J Cancer Res Clin Oncol. 2019 Feb;145(2):535-542
pubmed: 30603901
Lancet Oncol. 2018 Dec;19(12):1617-1629
pubmed: 30442501
J Exp Med. 2003 Aug 18;198(4):557-67
pubmed: 12913096
Mol Cancer Ther. 2017 Jul;16(7):1203-1211
pubmed: 28679835
Sci Transl Med. 2015 Apr 15;7(283):283ra55
pubmed: 25877893
Cancer Res. 2018 Oct 15;78(20):5958-5969
pubmed: 30154149
J Exp Med. 2009 Jul 6;206(7):1495-503
pubmed: 19528259
Cancer Lett. 2005 Oct 18;228(1-2):229-40
pubmed: 15951104
Nat Genet. 2015 Aug;47(8):872-7
pubmed: 26121086
Am J Cancer Res. 2018 Jul 01;8(7):1273-1287
pubmed: 30094100
Mol Biol Cell. 2004 Aug;15(8):3950-63
pubmed: 15215311
Cancer Lett. 2005 Oct 18;228(1-2):155-61
pubmed: 15923080
Oncotarget. 2017 May 23;8(21):35088-35102
pubmed: 28456791
BMC Cancer. 2004 Oct 07;4:73
pubmed: 15471548
Trends Immunol. 2018 Mar;39(3):173-184
pubmed: 29336991
Int J Lab Hematol. 2020 Feb;42(1):52-60
pubmed: 31821742
Cell Tissue Res. 2018 May;372(2):277-286
pubmed: 29305654
J Immunol. 2004 Feb 15;172(4):2352-9
pubmed: 14764704
Oncoimmunology. 2015 Jul 15;5(1):e1064578
pubmed: 26942080
Histopathology. 2008 Jul;53(1):73-80
pubmed: 18613926
Nat Rev Cancer. 2013 Jun;13(6):397-411
pubmed: 23702928
BMC Cancer. 2018 Mar 7;18(1):267
pubmed: 29514610
Cancer Cell. 2019 Feb 11;35(2):221-237.e8
pubmed: 30753824
Lancet. 2007 Jun 23;369(9579):2106-20
pubmed: 17586306
Clin Cancer Res. 2019 Apr 15;25(8):2560-2574
pubmed: 30655315
Cancer. 2017 Apr 1;123(7):1095-1105
pubmed: 27984660
Pediatr Blood Cancer. 2017 Jan;64(1):46-56
pubmed: 27654028
Pediatr Blood Cancer. 2015 May;62(5):770-5
pubmed: 25683142
Clin Cancer Res. 2012 Jul 15;18(14):3834-45
pubmed: 22615450
J Histochem Cytochem. 2005 Dec;53(12):1433-40
pubmed: 15956022
Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12640-5
pubmed: 15314238
Science. 2015 Apr 3;348(6230):56-61
pubmed: 25838373
Immunol Lett. 2014 Oct;161(2):168-73
pubmed: 24361820